Experience
Everbridge Enters Into Definitive Agreement to Be Acquired by Thoma Bravo for $1.8 Billion
March 1, 2024
Cooley advised Everbridge, a global leader in critical event management and national public warning solutions, on its definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Everbridge at approximately $1.8 billion.
Related contacts
Related Practices & Industries
Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179
February 14, 2024
Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.
Related contacts
Related Practices & Industries
Autolus Announces Strategic Collaboration With BioNTech, $350 Million Underwritten Offering
February 8, 2024
Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.
Related contacts
Related Practices & Industries
Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma
January 17, 2024
Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.
Related contacts
Related Practices & Industries
MannKind Announces up to $200 Million Royalty Purchase Agreement With Sagard Healthcare
January 2, 2024
Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.
Related contacts
Related Practices & Industries
Related news and events
Everbridge Enters Into Definitive Agreement to Be Acquired by Thoma Bravo for $1.8 Billion
Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179
Autolus Announces Strategic Collaboration With BioNTech, $350 Million Underwritten Offering
Admissions and credentials
California
New York